Zevra Therapeutics shares are trading higher after the company announced it will present top-line data from its Phase 2 clinical trial of KP1077 for idiopathic hypersomnia and said it demonstrated "meaningful benefits". Also, Maxim Group and and Roth MKM raised their respective price targets on the stock and JMP Securities initiated coverage with a Market Outperform rating.
Portfolio Pulse from Benzinga Newsdesk
Zevra Therapeutics shares rose after announcing positive Phase 2 trial results for KP1077 in idiopathic hypersomnia. Maxim Group and Roth MKM raised price targets, and JMP Securities initiated coverage with a Market Outperform rating.
September 24, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Zevra Therapeutics shares increased due to positive Phase 2 trial results for KP1077, leading to raised price targets by Maxim Group and Roth MKM, and a Market Outperform rating by JMP Securities.
The announcement of positive trial results is a significant milestone for Zevra Therapeutics, likely boosting investor confidence. The raised price targets and positive analyst coverage further support a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100